{"id":6904,"date":"2026-08-07T04:27:59","date_gmt":"2026-08-07T04:27:59","guid":{"rendered":"https:\/\/www.paytmmoney.com\/blog\/?p=6904"},"modified":"2026-08-07T04:28:50","modified_gmt":"2026-08-07T04:28:50","slug":"molbio-diagnostics-ipo-review","status":"publish","type":"post","link":"https:\/\/www.paytmmoney.com\/blog\/molbio-diagnostics-ipo-review\/","title":{"rendered":"Molbio Diagnostics IPO Review: Key Details, Company Overview & Financials"},"content":{"rendered":"

Molbio Diagnostics IPO is a book-built issue worth \u20b9939.70 crores, comprising a fresh issue of 0.25 crore shares aggregating to \u20b9200.00 crores and an offer for sale of 0.92 crore shares aggregating to \u20b9739.70 crores.<\/span><\/p>\n

The IPO will open for subscription on Aug 10, 2026 and close on Aug 12, 2026. The allotment is expected to be finalised on Aug 13, 2026, while the shares are proposed to be listed on the NSE and BSE on Aug 17, 2026.<\/span><\/p>\n

The price band has been fixed at \u20b9768 to \u20b9807 per share, with a lot size of 18 shares. Retail investors need a minimum investment of \u20b914,526 (18 shares), calculated at the upper price band. Kotak Mahindra Capital Co. Ltd. is the book-running lead manager, and Kfin Technologies Ltd. is the registrar to the issue.<\/span><\/p>\n

For detailed information on the company’s business, financials, risk factors, and the proposed utilisation of proceeds, investors should refer to the Moblio Diagnostics IPO <\/span>Red Herring Prospectus(RHP)<\/span><\/span><\/a> before making an investment decision.<\/span><\/p>\n

Company Overview<\/b><\/h2>\n

Molbio Diagnostics Limited is an Indian molecular diagnostics company focused on developing and manufacturing rapid, point-of-care diagnostic solutions. The company offers integrated diagnostic platforms, testing kits, reagents, and software that enable the quick detection of infectious diseases and other medical conditions, making advanced diagnostics accessible even in resource-limited settings.<\/span><\/p>\n

Its flagship Truenat\u00ae platform is a portable, chip-based real-time PCR system designed to deliver accurate test results within a short time. The platform supports testing for a wide range of diseases, including tuberculosis (TB), COVID-19, hepatitis, HPV, dengue, malaria, HIV, and several other infectious diseases.<\/span><\/p>\n

The company has built end-to-end capabilities across research and development, product design, manufacturing, and commercialization. Its products are used by hospitals, diagnostic laboratories, public health institutions, and government healthcare programs in India and international markets.<\/span><\/p>\n

Molbio Diagnostics focuses on innovation-driven healthcare solutions, supported by a broad test menu, strong R&D capabilities, and a growing global distribution network. The company aims to improve access to reliable molecular diagnostics through affordable, portable, and easy-to-use testing technologies.<\/span><\/p>\n

IPO Details<\/b><\/h2>\n
\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Particulars<\/th>\nDetails<\/th>\n<\/tr>\n<\/thead>\n
IPO Date<\/td>\n10 to 12 August, 2026<\/td>\n<\/tr>\n
Allotment<\/td>\nThursday, August 13, 2026<\/td>\n<\/tr>\n
Listing Date<\/td>\nMonday, August 17, 2026<\/td>\n<\/tr>\n
Face Value<\/td>\n\u20b91 per share<\/td>\n<\/tr>\n
Price Band<\/td>\n\u20b9768 to \u20b9807 per share<\/td>\n<\/tr>\n
Lot Size<\/td>\n18 Shares<\/td>\n<\/tr>\n
Issue Type<\/td>\nBook Building IPO<\/td>\n<\/tr>\n
Sale Type<\/td>\nFresh capital cum OFS<\/td>\n<\/tr>\n
Total Issue Size<\/td>\n1,16,46,246 shares (agg. up to \u20b9940 Cr)<\/td>\n<\/tr>\n
Fresh Issue<\/td>\n24,80,246 shares (agg. up to \u20b9200 Cr)<\/td>\n<\/tr>\n
Offer for Sale (OFS)<\/td>\n91,66,000 shares of \u20b91 (agg. up to \u20b9740 Cr)<\/td>\n<\/tr>\n
Shareholding Pre-Issue<\/td>\n11,27,59,750 shares<\/td>\n<\/tr>\n
Shareholding Post-Issue<\/td>\n11,52,39,996 shares<\/td>\n<\/tr>\n
Listing Exchange<\/td>\nBSE, NSE<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

(Compiled from RHP and market updates)<\/span><\/i><\/span><\/p>\n

Industry Context<\/b><\/h2>\n
    \n
  • India’s diagnostics market was valued at \u20b9 1,354.2 billion (USD 15.3 billion) in Fiscal 2026, with the in vitro diagnostics (IVD) segment accounting for 56.1% of the total market. The market is projected to reach \u20b9 2,356.5 billion (USD 26.6 billion) by Fiscal 2031, growing at a CAGR of 11.7%.<\/span><\/li>\n
  • The diagnostics market expanded from \u20b9 725.8 billion (USD 10.31 billion) in Fiscal 2021 to \u20b9 1,354.2 billion (USD 15.3 billion) in Fiscal 2026, registering a CAGR of 13.3%. Growth is supported by the rising burden of chronic diseases, increasing preventive healthcare awareness, an ageing population, and government healthcare initiatives.<\/span><\/li>\n
  • The IVD market, valued at \u20b9 760.5 billion (USD 8.6 billion) in Fiscal 2026, comprises immunodiagnostics, haematology, molecular diagnostics, clinical chemistry, and other diagnostic techniques. Among these, clinical chemistry holds the largest share at 31.0%, with a market size of \u20b9 235.7 billion (USD 2.6 billion), followed by immunodiagnostics at \u20b9 178.7 billion (USD 2.0 billion).<\/span><\/li>\n
  • Based on products, the IVD industry includes reagents, instruments\/devices, and diagnostic software. These products support testing, sample analysis, data management, and result interpretation across laboratories, hospitals, and healthcare facilities.<\/span><\/li>\n
  • Most diagnostic testing in India remains illness-focused, with only approximately 10% of tests related to wellness and preventive healthcare. At the same time, molecular diagnostics is gaining importance for the early detection and monitoring of infectious diseases, genetic disorders, and non-communicable diseases.<\/span><\/li>\n<\/ul>\n

    Business Strengths<\/b><\/h2>\n
      \n
    • The company’s Truenat platform provides rapid, point-of-care molecular testing and includes WHO-endorsed technology for tuberculosis diagnosis, strengthening its credibility and adoption across healthcare systems.<\/span><\/li>\n
    • Molbio Diagnostics continuously invests in innovation, supported by an extensive global patent portfolio that helps develop new diagnostic solutions and strengthens its competitive position.<\/span><\/li>\n
    • The company generates recurring income through the sale of diagnostic test kits and consumables used with its installed diagnostic systems, supporting long-term revenue growth.<\/span><\/li>\n
    • Molbio Diagnostics operates in more than 90 countries, serving governments, public health agencies, hospitals, and diagnostic laboratories through long-standing customer relationships.<\/span><\/li>\n
    • The company expands its product portfolio and market reach through acquisitions, collaborations, and partnerships that enhance its capabilities in molecular diagnostics and healthcare.<\/span><\/li>\n
    • The management team brings extensive experience in molecular diagnostics, medical technology, and healthcare innovation, supporting product development, operational execution, and long-term growth.<\/span><\/li>\n<\/ul>\n

      Business Risks<\/b><\/h2>\n
        \n
      • A significant share of the company’s revenue comes from government agencies and public healthcare programs. Any reduction in funding, policy changes, or delays in procurement could affect business performance.<\/span><\/li>\n
      • A substantial portion of revenue is generated from the Truenat diagnostic platform. Lower demand, technological disruptions, or product-related issues could impact the company’s financial performance.<\/span><\/li>\n
      • The molecular diagnostics industry is competitive, with global and domestic players introducing new technologies. Failure to keep pace with innovation may affect market share.<\/span><\/li>\n
      • The company operates in a highly regulated industry where product approvals, quality standards, and compliance requirements vary across countries. Delays or non-compliance could impact product launches and sales.<\/span><\/li>\n
      • Sustaining growth requires ongoing investment in research and development. Delays in developing new products or unsuccessful innovation efforts could reduce the company’s competitive advantage.<\/span><\/li>\n
      • With operations across multiple international markets, the company faces risks related to supply chain disruptions, geopolitical developments, foreign exchange fluctuations, and changing trade regulations.<\/span><\/li>\n<\/ul>\n

        Financial Performance<\/b><\/h2>\n

        Molbio Diagnostics Limited – Financials (\u20b9 in Million)<\/b><\/h3>\n

        <\/p>\n

        \n\n\n\n\n\n\n\n\n\n\n\n
        Particulars<\/th>\nFiscal 2026<\/th>\nFiscal 2025<\/th>\nFiscal 2024<\/th>\n<\/tr>\n<\/thead>\n
        Revenue from Operations<\/td>\n14,456.87<\/td>\n10,204.18<\/td>\n8,365.61<\/td>\n<\/tr>\n
        Total Liabilities<\/td>\n8,396.48<\/td>\n4,942.70<\/td>\n3,922.19<\/td>\n<\/tr>\n
        EBITDA<\/td>\n3,282.43<\/td>\n2,566.39<\/td>\n1,850.93<\/td>\n<\/tr>\n
        EBITDA Margin (%)<\/td>\n22.56%<\/td>\n24.97%<\/td>\n22.02%<\/td>\n<\/tr>\n
        Profit After Tax (PAT)<\/td>\n1,641.40<\/td>\n1,385.79<\/td>\n835.42<\/td>\n<\/tr>\n
        Return on Equity (ROE)<\/td>\n15.59%<\/td>\n16.20%<\/td>\n13.20%<\/td>\n<\/tr>\n
        Return on Capital Employed (ROCE %)<\/td>\n17.55%<\/td>\n20.98%<\/td>\n15.80%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

        <\/p>\n

        \u2190 Swipe horizontally to view full table \u2192<\/div>\n